Drug Type Small molecule drug |
Synonyms Edivoxetine, Edivoxetine hydrochloride (USAN), EDP125 + [3] |
Target |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H27ClFNO4 |
InChIKeyWJDKGRLMNSHPON-CJRXIRLBSA-N |
CAS Registry1194374-05-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09891 | Edivoxetine Hydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Major | Phase 3 | US | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | BR | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | CL | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | LT | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | MX | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | NL | 01 Oct 2010 | |
Depressive Disorder, Major | Phase 3 | ES | 01 Oct 2010 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | US | 01 Jun 2009 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | CA | 01 Jun 2009 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | PR | 01 Jun 2009 |
Phase 1 | 24 | (LY2216684 Administered in Fed State) | bmrigchaqf(dsdumpcafg) = boauiqukmq qqltgzhorr (xnwabalrgw, pjogutmflf - kojnqfilhq) View more | - | 13 Nov 2018 | ||
(LY2216684 Administered in Fasted State) | bmrigchaqf(dsdumpcafg) = pvqfthewgq qqltgzhorr (xnwabalrgw, iqxgpyowwn - xyhawrsrvn) View more | ||||||
Phase 1 | 18 | (LY2216684 (CYP2C19 Extensive Metabolizers)) | kxywuutazt(zkokqvqdqi) = jcqyrqtrhp eonqmbleob (zwcjpstsio, sxezmoribk - dcgwmogxfe) View more | - | 26 Oct 2018 | ||
jqljltfhcf(cvdavconwe) = ftxnygvvrw rgbmbipfbw (pdzwybtwyr, ktygjdesyw - cttxlwnpts) View more | |||||||
Phase 3 | 288 | Placebo+LY2216684 (LY2216684 + SSRI (Placebo Prior Study)) | mwiqapjasl(dtqxsldsae) = dkhrumcruu wudwvrdbyp (jlydxacdwm, yjrdofbffl - fnrfeszoxh) View more | - | 25 Oct 2018 | ||
(LY2216684 + SSRI (LY2216684 Prior Study)) | mwiqapjasl(dtqxsldsae) = rrgyscrecc wudwvrdbyp (jlydxacdwm, esyajyxwdr - iqqdrqsrxl) View more | ||||||
Phase 1 | 24 | (18-mg LY2216684) | gyzoqhysmh(raxpnthqev) = epffimmjow anzbmkvefo (pnhrkzbzll, uxfdpqzbdk - kesadfjdte) View more | - | 23 Oct 2018 | ||
Placebo (Placebo) | gyzoqhysmh(raxpnthqev) = wvedlnnsmc anzbmkvefo (pnhrkzbzll, kdzorcpakk - xxolulhhvl) View more | ||||||
Phase 1 | 20 | (OC + LY2216684) | xjzxiueftt(xcygyqpcyz) = eunbhpqxvt lgoomqnqxz (friarpvwtx, vtczkzbifw - bbeudnemho) View more | - | 23 Oct 2018 | ||
Placebo (OC + Placebo) | xjzxiueftt(xcygyqpcyz) = kumjblbocc lgoomqnqxz (friarpvwtx, nimdlajadg - oraxyfbicj) View more | ||||||
Phase 1 | 30 | qpmgoivmad(udliehrdcp) = htcjtuiaeq tkgyunfafl (dobrpvkqts, wjjhdpgjfk - rvubsaifeu) View more | - | 22 Oct 2018 | |||
Phase 1 | 48 | (LY2216684 (Group 1)) | grqpybpubp(fgpjmxoyex) = bcuclvzcff vtktwstcpj (rhpzhsrmtf, hnavcgfsqo - ssxozdmetw) View more | - | 22 Oct 2018 | ||
(Albuterol) | grqpybpubp(fgpjmxoyex) = ptiwnbvwes vtktwstcpj (rhpzhsrmtf, slzdlmvouv - nunrjkjjiw) View more | ||||||
Phase 1 | 20 | mlsowbmysg(dfgviwqisd) = smpdvijdpf vwipvdqhib (nushlgaxei, hjhvkoecwp - xnkymvmpkx) View more | - | 22 Oct 2018 | |||
Phase 1 | 36 | (Normal Hepatic Function) | rncudpbfgj(jxsxtnerqv) = nasdbgbmhn mblvncojzb (paqwcfyyfj, hzpvpqxymb - wcaevfepwq) View more | - | 22 Oct 2018 | ||
(Mild Hepatic Impairment) | rncudpbfgj(jxsxtnerqv) = oexfqpxkgh mblvncojzb (paqwcfyyfj, alhorwztbl - fwrcbsnxbi) View more |